Alcoholic Hepatitis - Pipeline Review, H2 2016

Introduction

Global Markets Direct Report Coverage

Alcoholic Hepatitis Overview

Therapeutics Development

Pipeline Products for Alcoholic Hepatitis - Overview

Pipeline Products for Alcoholic Hepatitis - Comparative Analysis

Alcoholic Hepatitis - Therapeutics under Development by Companies

Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes

Alcoholic Hepatitis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Alcoholic Hepatitis - Products under Development by Companies

Alcoholic Hepatitis - Products under Investigation by Universities/Institutes

Alcoholic Hepatitis - Companies Involved in Therapeutics Development

Alfact Innovation

Conatus Pharmaceuticals Inc.

Generon (Shanghai) Corporation Ltd.

Genextra S.p.a.

Gilead Sciences, Inc.

GRI Bio, Inc.

Immuron Limited

Promethera Biosciences S.A.

Verlyx Pharma Inc.

Alcoholic Hepatitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ALF-5755 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRI-0621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentamidine isethionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKM-02GI1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selonsertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcoholic Hepatitis - Dormant Projects

Alcoholic Hepatitis - Product Development Milestones

Featured News & Press Releases

Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients

Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Alcoholic Hepatitis, H2 2016

Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Alcoholic Hepatitis - Pipeline by Alfact Innovation, H2 2016

Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016

Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016

Alcoholic Hepatitis - Pipeline by Genextra S.p.a., H2 2016

Alcoholic Hepatitis - Pipeline by Gilead Sciences, Inc., H2 2016

Alcoholic Hepatitis - Pipeline by GRI Bio, Inc., H2 2016

Alcoholic Hepatitis - Pipeline by Immuron Limited, H2 2016

Alcoholic Hepatitis - Pipeline by Promethera Biosciences S.A., H2 2016

Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Alcoholic Hepatitis - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Alcoholic Hepatitis, H2 2016

Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016

Alcoholic Hepatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Alcoholic Hepatitis - Pipeline Review, H2 2016’, provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

• The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
• The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects
• The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline